Literature DB >> 2179226

Local and regional immunotherapy of cancer with interleukin 2.

J Bubeník1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2179226     DOI： 10.1007/BF01612631

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  34 in total

Review 1.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

Review 2.  Local immunotherapy of cancer with interleukin 2.

Authors:  J Bubeník
Journal:  Immunol Lett       Date:  1989-06-15       Impact factor: 3.685

3.  Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma.

Authors:  J Bubeník; J Kieler; V Tromholt; G Hermann; T Jandlová
Journal:  Immunol Lett       Date:  1988-06       Impact factor: 3.685

4.  Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically.

Authors:  G Cortesina; A De Stefani; M Giovarelli; M G Barioglio; G P Cavallo; C Jemma; G Forni
Journal:  Cancer       Date:  1988-12-15       Impact factor: 6.860

5.  Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report.

Authors:  J Bubeník; P Perlmann; M Indrová; J Símová; T Jandlová; J Neuwirt
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

6.  Three-dimensional structure of interleukin-2.

Authors:  B J Brandhuber; T Boone; W C Kenney; D B McKay
Journal:  Science       Date:  1987-12-18       Impact factor: 47.728

7.  Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.

Authors:  S Silagi; A E Schaefer
Journal:  J Biol Response Mod       Date:  1986-10

8.  Influence of the administration schedule on the therapeutic effect of interleukin-2.

Authors:  J Vaage; J L Pauly; J P Harlos
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

9.  Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563.

Authors:  R Maekawa; M Matsumoto; T Kitagawa; M Harada; K Sato
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  Local and systemic effects during interleukin-2 therapy of mouse mammary tumors.

Authors:  J Vaage
Journal:  Cancer Res       Date:  1987-08-15       Impact factor: 12.701
View more
  3 in total

1.  Utilization of interleukin-2 gene transfer in local immunotherapy of cancer.

Authors:  J Bubeník; J Símová; D Bubeníková; J Zeuthen; C Radzikowski
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

2.  Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment.

Authors:  J Bubeník; J Símová; D Bubeníková; J Zeuthen; M Indrová
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

3.  Membrane anchored immunostimulatory oligonucleotides for in vivo cell modification and localized immunotherapy.

Authors:  Haipeng Liu; Brandon Kwong; Darrell J Irvine
Journal:  Angew Chem Int Ed Engl       Date:  2011-06-17       Impact factor: 15.336
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.